

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-48. (Cancelled)

49. (Currently Amended) A method of treating hot flashes in a patient comprising:

administering to a patient that experiences hot flashes an effective amount of one or more compounds selected from the group of L-norleucine, L-alloisoleucine, L-methionine, 2-cyclohexylglycine, 2-phenylglycine, 2-amino-2-norbornane carboxylic acid, 1-aminocyclohexane carboxylic acid, 2-aminoheptanoic acid, 2-aminocaprylic acid, and 2-aminononanoic acid under conditions effective to treat the hot flashes.

50. (Cancelled)

51. (Currently Amended) The method according to claim 49 wherein the effective compound is administered in an amount of about 10 to about 5000 mg per day.

52. (Previously Presented) The method according to claim 49 wherein said administering is carried out orally, parenterally, subcutaneously, transdermally, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes.

53. (Previously Presented) The method according to claim 49 wherein the compound is present in a pharmaceutical composition comprising the compound and a pharmaceutically-acceptable carrier.

54. (Previously Presented) The method according to claim 53 wherein the pharmaceutical composition is in a liquid or solid dosage form.

55. (Previously Presented) The method according to claim 49 wherein the compound is present in a nutritional supplement comprising the compound and a suitable carrier.

56. (Previously Presented) The method according to claim 55 wherein the nutritional supplement is in a liquid or solid dosage form.

57. (New) A method of treating hot flashes in a patient comprising:
administering to a patient that experiences hot flashes an amount of one or more
compounds selected from the group of L-norleucine, L-alloisoleucine, 2-cyclohexylglycine, 2-
phenylglycine, 2-amino-2-norbornane carboxylic acid, 1-aminocyclohexane carboxylic acid, 2-
aminoheptanoic acid, 2-aminocaprylic acid, and 2-aminononanoic acid under conditions effective
to treat the hot flashes.

58. (New) The method according to claim 57 wherein the compound is
administered in an amount of about 10 to about 5000 mg per day.

59. (New) The method according to claim 57 wherein said administering is
carried out orally, parenterally, subcutaneously, transdermally, intravenously, intramuscularly,
intraperitoneally, by intranasal instillation, by implantation, by intracavitory or intravesical
instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes.

60. (New) The method according to claim 57 wherein the compound is present
in a pharmaceutical composition comprising the compound and a pharmaceutically-acceptable
carrier.

61. (New) The method according to claim 60 wherein the pharmaceutical
composition is in a liquid or solid dosage form.

62. (New) The method according to claim 57 wherein the compound is present
in a nutritional supplement comprising the compound and a suitable carrier.

63. (New) The method according to claim 62 wherein the nutritional
supplement is in a liquid or solid dosage form.

64. (New) A method of treating hot flashes in a patient comprising:
administering to a patient that experiences hot flashes an effective amount of
L-methionine under conditions effective to treat the hot flashes.

65. (New) The method according to claim 64 wherein the effective amount is
about 10 to about 5000 mg per day.

66. (New) The method according to claim 64 wherein said administering is
carried out orally, parenterally, subcutaneously, transdermally, intravenously, intramuscularly,

intraperitoneally, by intranasal instillation, by implantation, by intracavitory or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes.

67. (New) The method according to claim 64 wherein the compound is present in a pharmaceutical composition comprising the compound and a pharmaceutically-acceptable carrier.

68. (New) The method according to claim 67 wherein the pharmaceutical composition is in a liquid or solid dosage form.

69. (New) The method according to claim 64 wherein the compound is present in a nutritional supplement comprising the compound and a suitable carrier.

70. (New) The method according to claim 69 wherein the nutritional supplement is in a liquid or solid dosage form.